-Search query
-Search result
Showing all 36 items for (author: hoshino & a)
EMDB-35029:
SARS-CoV2 spike protein with ACE2, no ACE2 binding.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35030:
SARS-CoV2 spike protein with ACE2. 1 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35031:
SARS-CoV2 spike protein with ACE2. 2 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35032:
SARS-CoV2 spike protein with ACE2. 3 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35036:
SARS-CoV2 spike protein with ACE2 decoy.no ACE2 decoy binding
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35037:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35038:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound and 2 RBD up form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35039:
SARS-CoV2 spike protein with ACE2 decoy. 2 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35040:
SARS-CoV2 spike protein with ACE2 decoy. 3 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-36345:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
PDB-8jje:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-36905:
SARS-CoV-2 BA.1 RBD with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-36906:
SARS-CoV-2 BA.1 spike with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-35912:
Cryo-EM structure of the AsCas12f-sgRNA-target DNA ternary complex
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
EMDB-35926:
Cryo-EM structure of the AsCas12f-YHAM-sgRNAS3-5v7-target DNA
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
EMDB-35965:
Cryo-EM structure of the AsCas12f-HKRA-sgRNAS3-5v7-target DNA
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
PDB-8j12:
Cryo-EM structure of the AsCas12f-sgRNA-target DNA ternary complex
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
PDB-8j1j:
Cryo-EM structure of the AsCas12f-YHAM-sgRNAS3-5v7-target DNA
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
PDB-8j3r:
Cryo-EM structure of the AsCas12f-HKRA-sgRNAS3-5v7-target DNA
Method: single particle / : Hino T, Omura NS, Nakagawa R, Togashi T, Takeda NS, Hiramoto T, Tasaka S, Hirano H, Tokuyama T, Uosaki H, Ishiguro H, Yamano H, Ozaki Y, Motooka D, Mori H, Kirita Y, Kise Y, Itoh Y, Matoba S, Aburatani H, Yachie N, Siksnys V, Ohmori T, Hoshino A, Nureki O
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y